Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on the U.S. Food and Drug Administration’s review timeline for a potential focal ...

Q4 2025 Management View CEO Eric Dube stated that "2025 was an incredible year for Travere, one that was defined by achieving ...

Travere Therapeutics, Inc. ( TVTX) Q4 2025 Earnings Call February 19, 2026 4:30 PM EST Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2025 Financial Results ...

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of ...

Inc.), , a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address ...

The drug developer posted revenue of $129.7 million in the period, which did not meet Street forecasts. Six analysts surveyed by Zacks expected $142.5 million. For the year, the company reported a ...

Travere Therapeutics (NASDAQ: TVTX) reported its Q4 earnings results on Thursday, February 19, 2026 at 04:01 PM. Here's what investors need to know about the announcement. Travere Therapeutics beat ...

Learn more about whether IDEAYA Biosciences, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

Travere Therapeutics Inc reports fourth-quarter earnings Thursday after market close, with investors focused on the rare disease specialist’s commercial momentum following a regulatory setback that ...

Analysts anticipate Travere Therapeutics to report an earnings per share (EPS) of $0.24. The market awaits Travere ...

Travere Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Travere ...